Qlaris Bio
Wellesley
About Qlaris Bio
Qlaris Bio is a clinical stage biotechnology company that develops innovative first-in-class therapies for patients suffering from serious and debilitating ophthalmic diseases. Qlaris Bio is exploring novel mechanisms of action to address episcleral venous pressure (EVP), the largest component of intraocular pressure (IOP), to reduce the risk of blindness in glaucoma, including Primary Open Angle Glaucoma and Normal tension Glaucoma.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $49.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Apr 2024)
- Website: qlaris.bio
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/qlaris-bio-126974 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.